In this e-learning, lung cancer experts from different countries in Europe are discussing the challenges and opportunities in treating patients with ALK positive non-small cell lung cancer.
There are multiple next-generation ALK inhibitors available with distinct tolerance profiles and different dosing schedules.
Selecting a frontline ALK inhibitor has to do with several parameters but testing for ALK rearrangements is core in these patients.
Do you wish to learn more regarding ALK+ NSCLC from national and international experts? Start the e-learning!
MODULE 1 (theory)
Immunotherapy in 1st line among ALK positive patients
Prof. Joachim Aerts
Treatment of 1st line ALK+ patients: testing and sequencing
Dr. Laura Mezquita
MODULE 2 (clinical cases)
Lung Adenocarcinoma ALK+ cT4NxM1c (8aUICC)
Dr. Luis Paz-Ares
Treatment without knowing the genetic profile
Frontline treatment of ALK+ advanced NSCLC
Dr. Maurice Pérol
Professor of Pulmonology, in particular pulmonary oncology at the
Leiden University Medical Centre (LUMC), Leiden, the Netherlands
Head of the Medical Oncology
Department at the Hospital Universitario 12 de Octubre and
Associate Professor at the Universidad Complutense
Head of Thoracic Oncology in the Medical Oncology Department of Léon Bérard Cancer Center in Lyon, France
Head of the department of Pulmonary Medicine Erasmus MC, Rotterdam, The Netherlands.
Medical Oncologist, Juan Rodés Clinician-
Scientist in the Hospital Clínic of Barcelona, Spain